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Objective To investigate the role of ﬁbronectin in the pathogenesis of biomaterial-related infections and the
inﬂuence of catheter sepsis on the concentration of plasma ﬁbronectin during various stages of bacteremia.
Methods Plasma ﬁbronectin concentrations were determined by the simple radial immunodiffusion method.
Four groups of subjects were used: one group comprised patients with catheter sepsis, the second patients with
local inﬂammation of the catheter insertion site caused by slime-positive, coagulase-negative staphylococci, the
third patients with slime-negative, coagulase-negative staphylococci isolated from the catheter, and the fourth
demonstrably healthy persons.
Results In patients with catheter sepsis, ﬁbronectin concentrations were found after the disappearance of
catheter sepsis and 3–5 days after the removal of the catheter. A statistically signiﬁcant decrease in ﬁbronectin
concentration was detected in the plasma of patients with catheter sepsis compared with other groups of patients
and control subjects.
Conclusions The above results indicate a pathogenic role for ﬁbronectin in biomaterial-related infections.
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INTRODUCTION
Fibronectin is a high-molecular-weight glycoprotein found in
soluble form in the plasma and other body ﬂuids and in insoluble
form in many tissues. Fibronectin is intimately involved with
non-speciﬁc defense mechanisms of the body in close con-
nection with the monocyte–macrophage system. It is also
involved with maintaining hemostasis, where it interacts with
factors of the coagulase system, and also plays a role in cell
physiology and tissue organization [1,2]. Fibronectin was ﬁrst
mentioned by Morrison et al in 1948, when it was called ‘cold-
insoluble globulin’. Subsequently, it was given various names,
until, in 1978, it was termed ﬁbronectin [3].
Both forms of ﬁbronectin demonstrate afﬁnity for native and
denatured collagen, ﬁbrinogen or ﬁbrin, heparin and other
glycosaminoglycans, proteoglycans and surfaces of many sorts
of eukaryotic cells [1]. Fibronectin binds to staphylococci and
streptococci [4–6], and in 1991 Visai et al [7] reported the
binding of ﬁbronectin to an enterotoxigenic strain of Escherichia
coli B342289c. Fibronectin can also adhere to virus gly-
coproteins [8]. Adherence of coagulase-negative staphylococci
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on the surface of implants has been shown to be induced and
moderated by ﬁbronectin [9–11]. Direct production of the so-
called conditioning layer made up of the patient’s proteins on
the biomaterial surface exposed to blood has been observed
[11]. Studies with coagulase-negative strains of staphylococci
isolated from sepsis have shown that pathogenic strains usually
bind ﬁbronectin, collagen and laminin in different com-
binations [10,12,13].
It is believed that ﬁbronectin concentrations in patients’
plasma change with the adherence of coagulase-negative sta-
phylococci to catheters and other biomaterials. There are, how-
ever, no data in the literature regarding the dynamics of
ﬁbronectin concentration in plasma during the presence of the
catheter in a blood vessel and its concentrations immediately
after the removal of the catheter, respectively.
MATERIALS AND METHODS
Fibronectin concentrations have been investigated in the plasma
of seriously ill patients, all of whom had a venous catheter in
place, from intensive care units of different clinical departments.
The patients (27 women and 39 men) were aged between 43
and 85. The ﬁrst group comprised 26 patients with clinically
and microbiologically demonstrable catheter sepsis (symptoms:
fever to 38.5°C, often associated with shivering and sometimes
with hemodynamic changes (tachycardia, hypotension, low
central venous pressure, sometimes with leukocytosis)). The
122 Clinical Microbiology and Infection, Volume 6 Number 3, March 2000
positive staphylococcal culture was isolated from both the cath-
eter tip and hemoculture with the same species, resistogram,
and the same intensity of slime production. The second group
consisted of patients with local inﬂammation at the insertion
site of the venous catheter and of patients from whom slime-
positive, coagulase-negative staphylococci were isolated from
the catheters (15 patients). The third group comprised patients
from whom slime-negative strains of coagulase-negative sta-
phylococci were isolated (25 patients). The fourth, control,
groupwas made up of 20 blood donors aged 20–59, ﬁve women
and 15 men, healthy according to a medical examination. From
all patients, except the ones with catheter sepsis, single blood
samples were taken from a peripheral vein. The blood samples
from the patients with catheter sepsis were taken two more
times: on the day of the disappearance of the febrile state (23
patients) and 3–5 days after the removal of the catheter (23
patients). EDTA was added to the serum samples, which were
kept at –20°C until the determination of ﬁbronectin con-
centrations by the simple radial immunodiffusion method [14].
Electro-immunodiffusion was carried out using LC-Partigen
plates (Behringwerke AG,Marburg, Germany) [14]. The results
were treated statistically [15,16].
RESULTS
Table 1 shows the ﬁbronectin concentrations in patients with
catheter sepsis from whom slime-positive staphylococci in pure
culture were isolated. It is interesting to observe that, during
sepsis, ﬁbronectin concentrations were low in most patients
(0.120–0.220 g/L in 16/26 patients). After the symptoms of
sepsis disappeared, these concentrations were slightly higher
(0.221–0.320 g/L) in 17/23 patients), and concentrations were
higher still after the removal of the catheter (0.321–0.420 g/L
in 16/23 patients).
Table 1 Fibronectin concentrations in plasma of the patients
with catheter sepsis
Number of patients
During After After removal
Fibronectin (g/L) sepsisa sepsisb of the catheterc
0.120–0.170 5 1
0.171–0.220 11 5 2
0.221–0.270 9 12 1
0.271–0.320 1 5 4
0.321–0.370 – – 12
0.371–0.420 – – 4
Total 26 23 23
aDuring the febrile stadium. bIn the afebrile period. cThree to ﬁve
days after removal of the catheter.
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Figure 1 Mean ﬁbronectin concentrations (X¯) and standard devi-
ations (s) in plasma of the patients during sepsis (1), after the dis-
appearance of sepsis (2), and 3–5 days after removal of the catheter
(3). —, range of mean ﬁbronectin concentrations at different stages
of investigation; - - - and —-—, range of the mean ﬁbronectin con-
centration2 standard deviation.
The mean ﬁbronectin concentrations are shown in Figure 1.
Concentrations increased from the ﬁrst to the third stage of the
investigation, with the concentrations being lower during the
clinical syndrome of sepsis, slightly higher after its regression,
and reaching normal values 3–5 days after removal of the cath-
eter. Statistically signiﬁcant differences were established
between the mean values of ﬁbronectin concentrations in pat-
ients with catheter sepsis and those after the disappearance
of sepsis (P³ 0.05), between the ﬁbronectin concentrations
during sepsis and those after removal of the catheter (P³ 0.05),
as well as between the concentrations found after the dis-
appearance of sepsis and those after removal of the catheter
(P³ 0.05).
Signiﬁcant differences between ﬁbronectin concentrations in
patients of the second and the third groups when comparedwith
those in healthy subjects (control group) were found (P³ 0.05)
Table 2 Fibronectin concentrations in plasma of the patients
in the second, third and control groups
Number of patients
Second Third Control
Fibronectin (g/L) group group group
0.064–0.215 – 1 –
0.216–0.366 5 12 –
0.367–0.517 4 8 6
0.518–0.668 6 4 8
0.669–0.819 – – 6
Total 15 25 20
Groups of patients for which ﬁbronectin concentrations were com-
pared: 2 and 3 (P×0.05); 2 and 4 (P³0.05); 3 and 4 (P³0.05).
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(Table 2). No difference was found between patients of the
second and the third groups (P× 0.05). The ﬁbronectin con-
centrations varied as follows: in the second group of patients
0.216–0.668 g/L, in the third group 0.064–0.068 g/L, and in
Table 3 Comparison of ﬁbronectin concentration in different groups of patients: results of t-test (small independent samples)
Property
Groups to compare X¯1 X¯2 S1 S2 SX¯1–X¯2 t t·05 P
First group of patients
(in the course of sepsis)
 0.209 0.450 0.037 0.104 0.0073 −33.01 2.13 ³0.05
Second group of patients
First group of patients
(in the course of sepsis)
 0.209 0.397 0.037 0.114 0.024 −7.83 2.06 ³0.05
Third group of patients
First group of patients
(in the course of sepsis)
 0.209 0.587 0.037 0.105 0.025 −15.12 2.09 ³0.05
Control group
First group of patients
(after disappearing of sepsis)
 0.246 0.450 0.039 0.104 0.028 −7.29 2.13 ³0.05
Second group of patients
First group of patients
(after disappearing of sepsis)
 0.246 0.397 0.039 0.114 0.024 −6.24 2.06 ³0.05
Third group of patients
First group of patients
(after disappearing of sepsis)
 0.246 0.587 0.039 0.105 0.025 −13.75 2.09 ³0.05
Control group
First group of patients
(after the removal of catheter)
 0.338 0.450 0.051 0.104 0.029 −2.14 2.13 ³0.05
Second group of patients
First group of patients
(after the removal of catheter)
 0.338 0.397 0.051 0.114 0.025 −2.34 2.06 ³0.05
Third group of patients
First group of patients
(after the removal of catheter)
 0.338 0.587 0.051 0.105 0.026 −9.65 2.09 ³0.05
Control group
X¯, mean of sample; S, standard deviation of sample; SX¯1–X¯2, standard error in difference of means; t, arithmetic value; t·05, limiting value; P,
level of signiﬁcance 5%.
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 121–124
the fourth 0.367–0.712 g/L. The median values of the ﬁb-
ronectin concentrations in the second, third and fourth groups
were as follows: 0.461 g/L, 0.360 g/L and 0.593 g/L, respec-
tively. Fibronectin concentrations were compared for all four
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groups of subjects in all possible combinations (Table 3). It is
interesting that in all comparisons between groups, statistically
signiﬁcant differences were found between the mean values of
ﬁbronectin concentrations.
DISCUSSION
The concentration of plasma ﬁbronectin is reduced in the syn-
drome of disseminated intravascular coagulation (DIC), in pat-
ients with severe burns, injuries or sepsis, after major surgery,
in patients in a state of shock and in those with cirrhosis of the
liver [17]. A higher concentration of plasma ﬁbronectin is a
characteristic of intra- and extrahepatic cholestasis, and
signiﬁcantly higher levels have also been found in those with
pre-eclampsia. [17]. Reductions in ﬁbronectin concentrations
in patients with catheter sepsis could result from ﬁbronectin
being deposited on the intravascular catheter surface. In this
study, the ﬁbronectin concentrations in plasma have been deter-
mined also in seriously ill patients without intravascular cath-
eters or cannulae. Statistically signiﬁcant differences between
the ﬁbronectin concentrations in this group of patients and
those in the group with catheter sepsis have been demonstrated
(t=−7.46, t·05 = 2.06, P³ 0.05). As ﬁbronectin exists in two
forms—plasma and cellular—this increased deposition of plasma
ﬁbronectin on the inserted catheter surface would probably
lead to the increased synthesis and release of tissue ﬁbronectin
from cell surfaces, resulting in the concentration being brought
back to normal. That is, there is a permanent dynamic trans-
formation between these two forms of ﬁbronectin.
In the study of slime-positive and slime-negative coagulase-
negative staphylococcal strains isolated from the catheters in
our group of patients, it was found that, in catheter sepsis, S.
epidermidis, S. haemolyticus and S. hominis predominated,
whereas in slime-negative samples, S. xylosus strains predomi-
nated. The strains which caused the catheter sepsis were of
species reported to have receptors for ﬁbronectin on their
surfaces, while those which colonized catheters were slime-
negative strains, which are believed not to bind ﬁbronectin.
These results are in agreement with those reported by Switalski
et al [12]. At present, however, this remains only a hypothesis,
which is worthy of further investigation.
CONCLUSIONS
A signiﬁcant reduction in ﬁbronectin concentration in the
plasma of patients with catheter sepsis, compared with the
concentrations in patients with colonization of the catheter, has
been statistically proven. In addition, a signiﬁcant reduction
was seen in ﬁbronectin plasma levels in patients with sepsis
compared to those in healthy control subjects. These lower
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ﬁbronectin concentrations in plasma in the presence of an
indwelling catheter increased to normal values soon after the
removal of the catheter. These results suggest that the ﬁb-
ronectin concentration can predict the colonization of the cath-
eter with staphylococci. The data also indicate an indisputably
important role of ﬁbronectin in the adherence of staphylococci
to the polymer surface and thus in the pathogenesis of biom-
aterial-related infections.
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